

**SENATE STANDING COMMITTEE ON FINANCE & PUBLIC ADMINISTRATION**  
**References Committee**

**Inquiry into the Government's administration of the Pharmaceutical Benefits Scheme**  
**Answers to Questions on Notice**

Please see below Allergan's response to questions of notice posed by the Senate Committee following our appearance on Thursday.

*Q: What was the consultation process prior to deferral (of BOTOX® for severe axillary hyperhidrosis)?*

A: There was no consultation on the deferral. Allergan was informed of the Government's decision to defer the listing due to fiscal circumstances via a telephone call from the Department of Health and Ageing on the afternoon of 24 February 2011. The Minister publicly announced the deferral in her press release of 25 February 2011.

*Q: Does Allergan have costs associated with the deferral?*

BOTOX® is already PBS listed for a number of therapeutic indications and therefore Allergan had not ordered additional stock specifically in anticipation of a PBS listing for severe axillary hyperhidrosis.